Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05085561 · ClinicalTrials.gov registry record · Phase 2
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
A Phase 2 study, sponsored by Recursion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT05085561 is a Phase 2 study that has completed, run by Recursion Pharmaceuticals. The registered enrollment target is 62 participants.
The verdict
NCT05085561, a Phase 2 study, has completed, sponsored by Recursion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in participants with symptomatic cerebral cavernous malformation (CCM).
Interventions
- DRUG Placebo
- DRUG REC-994
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2022-03-17 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05085561
The ClinicalTrials.gov registry entry for NCT05085561 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Recursion Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05085561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05085561 about?
NCT05085561 is a clinical study titled "The Symptomatic Cerebral Cavernous Malformation Trial of REC-994". This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in participants with symptomatic cerebral cavernous malformation (CCM).
What is the current status of trial NCT05085561?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2022-03-17. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT05085561?
The interventions under investigation include: Placebo (DRUG), REC-994 (DRUG).
Who is sponsoring clinical trial NCT05085561?
This trial is sponsored by Recursion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.